Graybug Vision Revenue and Competitors

Location

$129.2M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Graybug Vision's estimated annual revenue is currently $6.6M per year.(i)
  • Graybug Vision's estimated revenue per employee is $947,571
  • Graybug Vision's total funding is $129.2M.

Employee Data

  • Graybug Vision has 7 Employees.(i)
  • Graybug Vision grew their employee count by -36% last year.

Graybug Vision's People

NameTitleEmail/Phone
1
VP, Regulatory AffairsReveal Email/Phone
2
VP, ControllerReveal Email/Phone
3
VP, Research & DevelopmentReveal Email/Phone
4
Chief Medical OfficerReveal Email/Phone
5
Associate Director, Pre-Clinical DevelopmentReveal Email/Phone
6
Accounts Payable SpecialistReveal Email/Phone
7
Laboratory TechnicianReveal Email/Phone
8
Research Associate IIReveal Email/Phone
9
Laboratory TechnicianReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$84.8M42224%N/AN/A
#2
$0.4M20%N/AN/A
#3
$32M1593%N/AN/A
#4
$35M1213%$62.5MN/A
#5
$30.2M15018%N/AN/A
#6
$135.3M6730%N/AN/A
#7
$110.3M549N/AN/AN/A
#8
$60.1M299-4%N/AN/A
#9
$554.8M17252%N/AN/A
#10
$10.5M524%N/AN/A
Add Company

What Is Graybug Vision?

Graybug Vision was founded in September 2011 as a spin-out of the world-renowned Wilmer Eye Institute of the Johns Hopkins University School of Medicine. Graybug Vision is a clinical-stage pharmaceutical company focused on developing the next generation of products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. Graybug Visionᅢᄁ¬ツᆲ¬トᄁs initial technology was co-developed by founder, Justin Hanes, PhD, who is the Lewis J. Ort Professor of Ophthalmology at the Wilmer Eye Institute of the Johns Hopkins University, in collaboration with co-founders and leading ophthalmology clinician-scientists from the Wilmer Eye Institute, Peter A. Campochiaro, MD and Peter J. McDonnell, MD. To address the burden of frequent intravitreal injections associated with managing patients with neovascular age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vascular occlusive disease (RVO), Graybug Vision is developing a proprietary depot formulation of sunitinib malate, GB-102. Sunitinib inhibits multiple biologic pathways known to be associated with angiogenesis, vascular permeability, fibrosis, while promoting neuroprotection to retinal ganglion cells and photoreceptors. To address the low compliance rate of self-administered eye drops for the treatment of elevated intraocular pressure (IOP) associated with primary open-angle glaucoma (POAG) and ocular hypertension (OHT), Graybug Vision is developing novel injectable compounds that will allow the physician to manage the pharmacologic treatment of disease rather than the patient. The company has established a portfolio of over 100 proprietary compounds to lower IOP and / or provide neuroprotection.

keywords:Biotechnology

$129.2M

Total Funding

7

Number of Employees

$6.6M

Revenue (est)

-36%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Graybug Vision News

2022-04-17 - GRAYBUG VISION, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

GRAYBUG VISION, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K).

2022-04-17 - Graybug to Present at the 2022 ASCRS Annual Meeting

BALTIMORE, April 18, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on...

2022-04-13 - Graybug Vision Appoints Dirk Sauer to Board of Directors

BALTIMORE, April 13, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on...

2021-05-12 - GRAYBUG VISION, INC. Graybug Vision Announces First Quarter 2021 Financial Results and Recent Corporate Developments

REDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate developm ...

2021-03-04 - Graybug Vision Announces Full Year 2020 Financial Results and Recent Corporate Developments

REDWOOD CITY, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate develo ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.5M70%N/A
#2
$0.1M775%N/A
#3
$0.7M70%N/A
#4
$0.5M7-42%N/A
#5
$1.1M70%N/A